Last checked at 11 Mar 2021 12:13
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Pledge of Shares
Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, on 10 March 2021, it was notified that Manuel, Llobet, Chief Executive Officer and PDMR, entered into a personal loan agreement on 9 March 2021, whereby security over 1,125,000 ordinary shares of 0.01 pence each in the capital of the Company was granted in favour of Banco Santander.
There is no change in Mr Llobet's beneficial shareholding in the Company and he continues to have an interest and voting rights in 3,325,000 ordinary shares, representing approximately 0.52% of the issued share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||
a)
| Name
| Manuel Llobet
| ||||||
2
| Reason for the notification
| |||||||
a)
| Position/status
| Manuel Llobet - Chief Executive Office and PDMR
| ||||||
b)
| Initial notification /Amendment
| Initial notification | ||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||
a)
| Name
| ALLERGY THERAPEUTICS PLC | ||||||
b)
| LEI
| LEIR97215202003301009534776 | ||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||
a)
| Description of the financial instrument, type of instrument
| Ordinary Shares
| ||||||
b) | Identification code | GB00B02LCQ05 | ||||||
c)
| Nature of the transaction
| Mr Llobet entered into a personal loan agreement with Banco Santander whereby security over 1,125,000 ordinary shares in the Company. Mr Llobet remains the beneficial owner of the shares subject to the pledge and retains full voting rights. | ||||||
d)
| Price(s) and volume(s)
|
| ||||||
e)
| Aggregated information
| n/a | ||||||
f)
| Date of the transaction
| 9 March 2021 | ||||||
g)
| Place of the transaction
| Outside a trading venue | ||||||
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.